<SEC-DOCUMENT>0001193125-23-261154.txt : 20231024
<SEC-HEADER>0001193125-23-261154.hdr.sgml : 20231024
<ACCEPTANCE-DATETIME>20231024063530
ACCESSION NUMBER:		0001193125-23-261154
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20231023
FILED AS OF DATE:		20231024
DATE AS OF CHANGE:		20231024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231341112

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d572572d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October 23, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d572572dex991.htm">Immutep&#146;s Efti in Combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 23, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d572572dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g572572dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep&#146;s Efti in Combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Generates Excellent Overall
Survival Benefit in Patients with Metastatic <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Median Overall Survival reaches 35.5 months in first-line treatment of metastatic <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients expressing <FONT STYLE="white-space:nowrap">PD-L1</FONT> (TPS </I><I><U>&gt;</U></I><I>1%), 23.4 months in patients with low <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression (TPS <FONT STYLE="white-space:nowrap">1-49%),</FONT> and has not been reached in patients with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (TPS </I><I><U>&gt;</U></I><I>50%), exceeding expectations</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Promising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible
across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups (TPS </I><I>&lt;</I><I>1%, </I><I></I>&#8805;<I></I><I></I><I>1%, <FONT STYLE="white-space:nowrap">1-49%,</FONT> and </I><I></I>&#8805;<I></I><I></I><I>50%), differentiates
</I><I>efti</I><I> in combination with </I><I>KEYTRUDA</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> </I><I>from other chemotherapy-free immuno-oncology combinations in <FONT STYLE="white-space:nowrap">non-small</FONT> cell
lung cancer</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Exceptional durability and quality of responses exhibited through overall survival (OS) and progression free
survival rates across patients expressing <FONT STYLE="white-space:nowrap">PD-L1,</FONT> including <FONT STYLE="white-space:nowrap">3-year</FONT> OS rates of 45.6%, 31%, and 63.6% in TPS </I><I><U>&gt;</U></I><I>1%,
<FONT STYLE="white-space:nowrap">1-49%,</FONT> and </I><I><U>&gt;</U></I><I>50%, respectively</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Immutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday,
October 22nd, at 5PM ET)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 23</B><B></B><B>&nbsp;October </B><B>2023 &#150;</B> <U>Immutep Limited</U>
(ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces
excellent new clinical data from the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> / <FONT STYLE="white-space:nowrap">KEYNOTE-798</FONT> Phase II trial evaluating eftilagimod alpha (&#147;efti&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway,
NJ., USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment for patients with previously
untreated unresectable or metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The updated <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> data, with a <FONT STYLE="white-space:nowrap">cut-off</FONT> date of August&nbsp;15, 2023 and a median follow up of over 2 years (25.1 months), was presented by Dr.&nbsp;Enric Carcereny, Catalan Institute
of Oncology (ICO), Badalona, Spain, during a Mini Oral session (#1312MO) at ESMO Congress 2023 on Saturday, October 21st. Key takeaways from the oral presentation detailing results from efti in combination with KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for frontline treatment of advanced or metastatic NSCLC in the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promising Overall Survival (OS), Overall Response Rate (ORR), Progression Free Survival (PFS), and Duration of
Response (DOR) are visible across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups (Tumor Proportion Score [TPS] &lt;1%, &#8805;1%, <FONT STYLE="white-space:nowrap">1-49%,</FONT> and &#8805;50%), which clearly differentiates efti in
combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> from other chemo-free immuno-oncology (IO) combinations for first-line treatment of NSCLC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A significant overall survival benefit was achieved, with a <FONT STYLE="white-space:nowrap">35.5-month</FONT>
median Overall Survival (mOS) in patients with TPS &#8805;1%, <FONT STYLE="white-space:nowrap">23.4-month</FONT> mOS in TPS <FONT STYLE="white-space:nowrap">1-49%,</FONT> and mOS not yet reached in TPS &#8805;50%. Notably, the mOS in TPS &#8805;1%
was attained with central assessment of <FONT STYLE="white-space:nowrap">PD-L1</FONT> (N=58) and a larger patient group with central + local assessment of <FONT STYLE="white-space:nowrap">PD-L1</FONT> (N=71), and the
<FONT STYLE="white-space:nowrap">35.5-month</FONT> mOS compares very favourably to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> IO, <FONT STYLE="white-space:nowrap">IO-IO,</FONT> <FONT
STYLE="white-space:nowrap">IO-chemo,</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> therapies <I>(Table 1).</I> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g572572dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exceptional durability and quality of responses are increasingly evident with strong overall survival (OS) and
progression free survival (PFS) rates across patients expressing <FONT STYLE="white-space:nowrap">PD-L1.</FONT> The <FONT STYLE="white-space:nowrap">3-year</FONT> OS rates are 45.6%, 31.0%, and 63.6% in TPS <U>&gt;</U>1%, TPS <FONT
STYLE="white-space:nowrap">1-49%,</FONT> and TPS <U>&gt;</U>50%, respectively. The <FONT STYLE="white-space:nowrap">12-month</FONT> PFS rates are 46.8%, 42.1%, and 55.0% for TPS <U>&gt;</U>1%, TPS <FONT STYLE="white-space:nowrap">1-49%,</FONT> and
TPS <U>&gt;</U>50%, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The entire patient population regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (N=114)
showed encouraging efficacy with <FONT STYLE="white-space:nowrap">20.2-month</FONT> mOS, <FONT STYLE="white-space:nowrap">21.6-month</FONT> mDoR, and a <FONT STYLE="white-space:nowrap">36-month</FONT> OS rate of 36% despite ~75% of patients having
negative or low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Overall Survival of Efti +
KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> versus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> IO, <FONT STYLE="white-space:nowrap">IO-IO,</FONT> <FONT
STYLE="white-space:nowrap">IO-chemo,</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-chemo</FONT></FONT> therapies for first-line treatment of advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung
cancer patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS </B>&#8805;<B></B><B>1% </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g572572g94d41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* <I>NSQ</I><I> </I><I>=</I><I> </I><I>Non-squamous;</I><I> </I><I>SQ</I><I> </I><I>=</I><I>
</I><I>Squamous</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In NSCLC patients with <U>&gt;</U>1% <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, a key area for efti&#146;s future
development where it has FDA Fast Track status, the ORR (48.3%), mPFS (11.2 months), mDOR (24.2 months), and mOS (35.5 months) compare overall favourably to historical results of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy, as well as to historical results of approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> +
chemo-containing regimens. Collectively, the breadth of efficacy and safety data from the large number of metastatic NSCLC patients in the Phase II <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial offers compelling evidence of efti&#146;s
substantial impact in safely stimulating the patients&#146; immune response to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Enric Carcereny stated, &#147;The strong efficacy
data across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression in <FONT STYLE="white-space:nowrap">TACTI-002,</FONT> especially in <FONT STYLE="white-space:nowrap">PD-L1</FONT> low <FONT STYLE="white-space:nowrap">(1-49%)</FONT>
and <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative (&lt;1%) patients, differentiates efti in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> from other chemo-free immuno-oncology
combinations in the frontline treatment of advanced or metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. Unlike other <FONT STYLE="white-space:nowrap">IO-IO</FONT> combinations that only work in high <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expressing patients or <FONT STYLE="white-space:nowrap">IO-chemo</FONT> combinations that rely on toxic chemotherapy to drive better efficacy, efti is clearly enabling deep, durable responses for patients
regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression with a favourable safety profile that&#146;s in line with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Voigt, Immutep CEO stated, &#147;We are extremely pleased to report these excellent overall survival results, the gold standard benchmark within
oncology, in patients with metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, and believe these are among the strongest ever delivered in a sizable Phase II clinical trial like
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> evaluating a dual immuno-oncology approach. The strength of the data positions us well as we continue to plan and prepare for our Phase III trial that we expect to launch next year.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g572572dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will host a conference call and webcast to discuss the clinical data presented at ESMO 2023 and provide an overview on future clinical development
plans for efti in 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. The event will feature CEO Marc Voigt, CSO Dr Frederic Triebel, CMO Dr Florian Vogl, and Christian Mueller, Senior Vice President Strategic Development.
An open question&nbsp;&amp; answer session with all presenters will conclude the event. A replay of the webcast will be available under the Events section of Immutep&#146;s website. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Date/Time</U>: Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Register</U>: Link to register <U>here</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Questions</U>: Investors are invited to submit questions in advance via <U>immutep@citadelmagnus.com</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lung cancer is the second most common cancer. <FONT STYLE="white-space:nowrap">Non-small</FONT> cell lung cancer accounts for
approximately <FONT STYLE="white-space:nowrap">80-85%</FONT> of all lung cancers, impacting an estimated 1.87&nbsp;million people annually, and is the highest cause of death among all cancers<SUP STYLE="font-size:75%; vertical-align:top"><FONT
STYLE="white-space:nowrap">4-6</FONT></SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck
Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g572572dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1)
Clinical data according to iRECIST. Comparable results by RECIST1.1. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2) Arrow lengths in Table 1 are proportional representations of OS data. Data
for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapies taken from publications of respective registrational trials (e.g., <FONT STYLE="white-space:nowrap">KN-042,</FONT> <FONT
STYLE="white-space:nowrap">KN-189,</FONT> <FONT STYLE="white-space:nowrap">KN-407,</FONT> <FONT STYLE="white-space:nowrap">CM-227,</FONT> <FONT STYLE="white-space:nowrap">CM-9LA),</FONT> and comparison of data is from different clinical trials.
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3) Ipi+ Nivo approved in US for 1L NSCLC <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS <U>&gt;</U>1% but not in EU; Pembro monotherapy not
approved in Europe for TPS <FONT STYLE="white-space:nowrap">1-49%.</FONT> </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4) The Global Cancer Observatory,&nbsp;<U>Lung Cancer Fact Sheet</U>
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>5) American Cancer Society,&nbsp;<U>About Lung Cancer</U> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>6) CDC,&nbsp;<U>Lung Cancer Statistics</U> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264
George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g572572dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g572572dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M &2RQPQM)*X1%&2S' %&PFTE=F#-XSTJ*0JIFE _B1./UK-U(G.\331HZ;K=
MAJF1;39D R4888?A5*2>QK"K&>QH51H% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@##UG4-$M[J.+
M4X$DE0;T+0[]OT/X5+FHZ,RG6A!V9JO>0167VMWV0! ^XCH*=U:Y?,DN9[&-
M+XRTF,X5II/=8_\ '%1[2)@\331)9^+-+NY1%YCPL>GFK@'\::J18XXB$G82
MZ\6Z3;.4$KS$=?*7(_.DZD4$L13CH3Z=XCT[4I1##*4E/1)!@GZ4U-,J%:$W
M9&E//%:P/-,VR-!EF]!5-V-6U%79AR^,M)C.%:63W6/_ !J/:1.=XFFB2T\6
M:5=RB+S'A8\#S5P/SH52+''$0D[!=>+=*M7*"5IF'7RER/SH=2*"6(IQT)M/
M\2:=J4HABE9)3T208)^E-33*A6A-V1?O+N*QLYKJ<D11*68@9.!5FQGZ/XDT
MW7)I8K&1V:-0S;D*\4 6]3U.VTBQ:\NV985(!*KD\G'2@"'1]=L=<BEDL79E
MB8*VY2O- 'E>ISI:^/9[B4D1Q7N]B!G@,": .^'Q T D 3R_]^C0!TX.0"*
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y]XV_Y#2?\
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MO0C ''!8 T =^/ &@ Y$$O'_ $U:@!WC;5I-)\/,+=BDUPPB5AU48Y/Y#]:
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H \^\;?\AI/^N _F:YZNYYN*^,Z74_^1-D_P"O9?Y"M)?
M=53^#\C%\"?\?%[_ +J_S-12ZF&$W9<\<_\ (-M?^NW]#55=C3%_"BUX-_Y%
M]?\ KHU.G\)6&_AF!XW_ .0Q%_UP'\S6=7<Y\5\?R.CO?^1+;_KT7^0K1_ =
M4_X/R,3P)_Q]WG^XO\S44MSGPF[+_CC_ )!5O_UV'_H)JJNQIBO@1-X+_P"0
M#_VU;^E.G\)6%_AF)XX_Y"T'_7$?S-9U=SGQ7QHW=01I/ 4RJ,G[#_[+6\=D
M=U/X$<A\,YD36+R(D!GA!4>N#_\ 7IEG4^/O^12N/]]/_0A0!E?#'_D'ZA_U
MU7_T&@#F+\B+XAR,_ %^I)/IN% 'L5 '$?$R%WT>SF ^6.?#>V0?\* .<\,>
M$;/Q%823-?O%-&^UHU0' ['_ #Z4 ;O_  J^U'_,3E_[]B@#:L]!3P]X8U&U
MCG:8.DC[F7&/DQC]* .-^&W_ ",4O_7LW_H2T >F7]Q'9Z?<7$K!8XXV8D_2
M@#ROX?Q/+XKB=1Q'&[-[<8_K0!Z[0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MWA2YB\(O'>?\?*6963YL_,$YY[T >1Z%:ZI=7I_LAG6ZCC+_ "/M)'&?Y]*
M-JYT_P ::P!:W<5T\>>DA5$^I]: .W\)^&%\/6CM*ZR7DV/,9>B@=%% '14
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 P2(TK1!@74 D>@.<?R- "27$,4D4<DBJ\IVH"?O'&>* &SW4%KM\U
M]I;[H ))^@'- $D<BRQJZ'*L,@XH B2\@>X-NLG[T9^4@C..N/7\* )))4BV
M[V"[F"C/<GM0 B3Q/-)"LBF2/&]0>5STH C^W6HMOM/GIY&[;OSQG.WK]>*
M)&GBCFCB:11))G8I/+8ZXH :;J!8WD,BA(VVL?0^E #A/$;@VXD7S@N\IGG;
MG&: &->6Z6XN&E41'HWK]/6@!([VWEB>1),K']X8.5^HZT -BU&UG21HY<K&
M"6.T@#'6@";SH]T:[QF090>O>@"..^MI9C#')N<$J<*<9'7GI0 BZA:O/Y*S
M#S-Q3&",L.H!Z$T 2O<11S1PO(JR2YV*3RV.3B@".>_MK5]DTH1MN[&"<#U/
MH* )%N(FD$:R*6V;P >J^OTH JZC*DVA7DD;!D:W<J1W&TT >;_#;_D8I?\
MKV;_ -"6@#U:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H SR9H-5GD%M))'+'&H9-N 06SG)'J* *U]87
MMY<3RH\<810L&]22""&W#!XYP/\ @- $["X2^BO3;,X:#RW12-T9SGN>1V_
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (?M5O_S\1_\
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M?_GXC_[[%%T',NX?:K?_ )^(_P#OL470<R[A]JM_^?B/_OL470<R[A]JM_\
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M_OL470<R[A]JM_\ GXC_ .^Q1=!S+N'VJW_Y^(_^^Q1=!S+N'VJW_P"?B/\
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M?]]+_C1R2[!]7J=@_P"$7UC_ )\6_P"^E_QHY)=@^KU.P?\ "+ZQ_P ^+?\
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M4[!_PB^L?\^+?]]+_C1R2[!]7J=@_P"$7UC_ )\6_P"^E_QHY)=@^KU.P?\
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M\6_[Z7_&CDEV#ZO4[!_PB^L?\^+?]]+_ (T<DNP?5ZG8/^$7UC_GQ;_OI?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
.. * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g572572g94d41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g572572g94d41.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MZ=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH
M/[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_
M]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_
M "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_
MZ=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH
M/[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_
M]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_
M "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_
MZ=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH /[9_Z=O_ "-_]JH
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M6%[>6\-TJ\,L-U.@/1VH [V@ H * "@ H * "@ H * "@ H * "@ H GNO\
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M*I !^B- !0 4 % !0 4 % !0 4 % $]U_P ?-Q_UWE_]&-0!!0 4 % !0 4
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M@I$Q74Q:3.\:FP;'-^'_ -E+XX'PQ\5O#P^&&M:'X>\5>/OV1O$FD>&M6O\
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M0!V- &5J=M-<>1Y*;MGF;OF1<;O+V_>8?W3T]* ,K^S;W_GC_P"1(O\ XY0
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M !R@ _LV]_YX_P#D2+_XY0 ?V;>_\\?_ ")%_P#'* #^S;W_ )X_^1(O_CE
M!_9M[_SQ_P#(D7_QR@ _LV]_YX_^1(O_ (Y0 ?V;>_\ /'_R)%_\<H /[-O?
M^>/_ )$B_P#CE !_9M[_ ,\?_(D7_P <H /[-O?^>/\ Y$B_^.4 ']FWO_/'
M_P B1?\ QR@ _LV]_P">/_D2+_XY0 ?V;>_\\?\ R)%_\<H /[-O?^>/_D2+
M_P".4 ']FWO_ #Q_\B1?_'* #^S;W_GC_P"1(O\ XY0 ?V;>_P#/'_R)%_\
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MX: ^+O\ T-O_ )0?#/\ \I:Y/[3QO_/[_P DI_\ R)X_^M&>_P#0=_Y1P_\
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MCA__ )4'_#0'Q=_Z&W_R@^&?_E+1_:>-_P"?W_DE/_Y$/]:,]_Z#O_*.'_\
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M)F=1*K)_NJUHPBV]H345&,7TC)))[2L[.7UO7MGW(4 % 'C?[0.J:GHOP?\
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MI\*MHMD-X+!M23PE%J4(TI)TH6=.%N6FURZPC9<L'[JLK)%)?AYX 2Q_LQ?
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M?^FXGY#Q1_R/<=_W!_\ 4>D>-UPG@!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 >[?!WX-7WQ NTU?5A-8>$;2?;-. 8Y]8EB;Y['3V/W8@1MFN1D)RB9D
MSY7HX' 2Q+4YWC0B]7UE;I']7TV6NWTN0</U,SFJ]>]+ 4WJ]I56MX0[+I*?
M397E?E_0_3]/LM*LK73=-M8;*PLH4M[6TMT$<,$,8VI&B+T '?J2222237T\
M8QIQC""48Q5DELDC]4I4J="G"C1@J5*FE&,8JRBELDBY5&@4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\W>/OVHO '
MPZ\6ZMX-UO1_&%UJ>C_8/M,^E:?HL]@_]H:99ZI#Y$MWX@MI6VV]]$K;X$PZ
MN!N4!F .._X;8^%?_0 ^('_@J\.?_-70 ?\ #;'PK_Z 'Q _\%7AS_YJZ #_
M (;8^%?_ $ /B!_X*O#G_P U= !_PVQ\*_\ H ?$#_P5>'/_ )JZ #_AMCX5
M_P#0 ^('_@J\.?\ S5T '_#;'PK_ .@!\0/_  5>'/\ YJZ #_AMCX5_] #X
M@?\ @J\.?_-70 ?\-L?"O_H ?$#_ ,%7AS_YJZ #_AMCX5_] #X@?^"KPY_\
MU= !_P -L?"O_H ?$#_P5>'/_FKH /\ AMCX5_\ 0 ^('_@J\.?_ #5T '_#
M;'PK_P"@!\0/_!5X<_\ FKH /^&V/A7_ - #X@?^"KPY_P#-70 ?\-L?"O\
MZ 'Q _\ !5X<_P#FKH /^&V/A7_T /B!_P""KPY_\U= !_PVQ\*_^@!\0/\
MP5>'/_FKH /^&V/A7_T /B!_X*O#G_S5T '_  VQ\*_^@!\0/_!5X<_^:N@
M_P"&V/A7_P! #X@?^"KPY_\ -70 ?\-L?"O_ * 'Q _\%7AS_P":N@ _X;8^
M%?\ T /B!_X*O#G_ ,U= !_PVQ\*_P#H ?$#_P %7AS_ .:N@ _X;8^%?_0
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M?ASJFDZ)XYTS7=-U?2K6Y\*:]HFKZWIMG=Z1K<6GW\4TSQ_9BUO,(@#QZ_\
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M>)?"TF@/X;L+R"PO]6C\21ZT=)DMK2YN8!<!;TO D@EE5(LN #HK3X#^*?[
M\>ZIK-UI>@:CX*M_"]U!I=]K/AA;76K;Q+<0B*[CUV3Q'%9V=@ME.DMO=@W$
M-[.LEC;N;J&2- #6^*/P'U7PIJC-X/M+[6O#T.G^$GGEN=8T"]UN#4O%/EVE
ME'+H]B]O?16=SJK-:VTSV C=T9!*[(V #QOQ-X4UGP?J#:7KHTN+4(GGBN+7
M3?$/A_7Y+.>UF>WN+6_.@:I>KI]Y'/&Z-;W)BE!4Y3 H YR@ H * "@ H *
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M&I_#?X1_#WP3KEQ;7>OZ!X8TZW\0W-D&6QF\1W$9OO$#V"LS,NG_ -LW5]Y
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MU>G3=.U02Z7+<SVHM]3MENK=-]W:6TGG+&P#CR]H/W68<T <70 4 % !0 4
M% !0 4 % !0 4 % !0!W_P -_B1XD^%WB2W\1>';C:R[8=1TV9G-AK%AO#26
M5[&IY4XRDH^>)P'0@@@FWR#;Y'[!_#3XE^&_BEX;@\0^'I]K+LAU32IG0W^C
M7^S<]I=HO53@M%,HV3(-RX(94 /0J "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#P/]J'1M>\0? 7XCZ-X7L+K4O$%]I5A%I-G9:5>
MZW<27::YI4J.-(TZ2.YU"*(1M+)##+"S1Q/B2/[Z@'SC\8OAC\9?"/AW4?$5
MGX^O=1U?XI?%WPKJ?QO\0?"SX6?%* :-X&\._#F_\+>&8?"7P\^$7Q4B^)L\
M)\5Z-X&;5[S0O'DNJ-%<W,DF?#EK=Z0QL&Q4MO 'Q&\5Z3\.]$U+XE_'O7?#
M]A\$_P!H?5'\1^'K/XY? +5+_P 61^/O X^%VB>(],\1>(9O&R:WH>AW.L66
MD_\ "2:W>:MK=KH4U]?SZK'?7[WH!FZ[X%^*UK\+_B/H\4_QM\8ZEX^_9L\#
M>)M6MO$&HZSXGU$_&>]U_6)O$MOX1T[Q6&T/P5K3P7ML)/"VEVNDZ)9IIUA_
MQ*[2"&1I "[IVB^-O$EIXIT;P+J'[3&E?"/7?BK\"[73KWQGJGQMT+XI6\=U
M)<0_&U--U7XEM'X\\._#V31!X5B-VLEG96M[-K]QHL]K(GVB( O^-=+\;Z7X
M[\3:%I<_[2+>.]'\3?"72_V?;G0-5^+VM?"9_A?I]CX'B\0S_$/7YKJ[\":_
MK)U2/XH'Q'?_ !/NKWQ-=6?V-M+EGNWT(L >R_M&^&?C+KVI?"R7X<>(/!]A
MI&G_ !+\%WEY8ZS\*O%7CG4M.U*UGUEG\47^JZ%\4_#L,/A2UM9;6.>P?3HI
M/,S(=6B658HS] _0D^/\VKZ)%^SIXCU33/$7BA?!OQKTC6?&EU\._A[XT\63
MVUJ?A+\5-"N]=MO!?A"T\2ZW::,^NZOI\*H#J)MO[1MXYKF3F5S8-CPB^T[Q
M5_Q7'C>V\+_&+P9\#_B;^T9HWB3Q1H7@'1_B'X<^+]YX'L_A';:!>>,[7P;X
M%MH/'_@NT\0_&K0_#EWJ=IHMM8^(KC3([G4-4MH+;5=5C)L&QM>$_$7Q'\"Z
MQ\+/$VN6/Q^UOX6MJO[0V@:1I=[X=^(?C7QQ_8.N:]X,O_@I+\1/#MK8WOB*
M)5TK0O%EOI^L^.(%U+3;75+*+Q'=V>H7UX:-@V/&+_2?B"WAOPEK?C#2_P!J
M:W\?7G[&7P[TG0=4\ VWQ5BUY_CW:R>/;O3M+\?ZIX2S*VO6VHZA'--#XWG;
MPI&]X\GB?'FZ>S&WD&WD>A_$W1_CE::?\1KK3?\ A)O#8U_XQ?!N7XF^(/"O
M@[XG>)]1N?!D7P#\/:1KNH>"]%^#WBCPQXW\065O\5+;PU:WDG@K7;6\M[.V
MU1IS+8VFH6LQMY!MY%OP[X'NXO%7[*_C+QCXA^.OQ M]-?XH^&H/%6G>%?VH
M?AU+I-_J7C?PU?\ P\TCX@_#K5/$VJ>)M.\*P1Z;JNF7FO\ Q$EOK36-/TC3
MKCQ-J-[:26DSFWE8-O*QZ[XCO[3X>?'CXA^*/'?@#QMXNT/XB_#3P3X9\%Z]
MX-^&?B_XJ10V/AF]\5?\)=\.-=M?!_A[57\'P7FH^)--U5)]92QTK55U&8/>
M,^A3):FP;'GK_#_QAI/Q ^*'Q$\.V/Q3\/ZA_P -5? "VT'PSI&J>*-/\%WO
MPUU3X6_LQ^"/B)J=[X)T"\_X1WQ?I-GI'_"5V%SJ]W!JMMI$W@N5[&YLY=,N
MY)#;R#;R.1^'UC\;W^)OCG4_%WQ ^)MEXI5_C5:W?@5/@_\ M'/X/UC0!)XB
M3X<Q^&_B5>_$;5/@UIKP:;!X-U+3[WPGX7T/7Y_LKZ;?RG4K[6A>FP;&?J'P
MD^*ECX0\2:G8^.?VH[OQ!:?LEZ?X_P!-M9/B1\3KF2^_:0L;'Q)=V\T>G)=@
MMKB3BUM)OA_:)#X=NUNH/MWANYN(;.:V .W\?O\ $6\^(OBXX_:!M?B<WBWX
M5M\#AX*3XF6_P2A^'K6O@FX\6#QB-+!^&CW2:X_Q4&N+\0/,UTZ>MA'H8:8>
M'UH ]O\ BNCGXV_ I+^SNM1\/ZAX8^.^B1Z;:RPV\VH^,KOPQX9U'1;"QNI[
MJT2UU>?P=HWQ'2"5KRU58S=%I8U!DC /D6WT?Q5=^#9?#/AGP/\ $GXC?!3X
M9C]G36'MOB+\$M9^&_QAU/P3\./&T^I:O\'WTW7?#?AQ_C38>$]#M8O$.G6U
MAX=C>X87&D"]\1:QK+^8;>5@V\K'2_$?XF_#SQ)\2?BQXBN]&\8>#M!F_9 ^
M)GA74;KXE_##QY\+6^+5W;O=^)QH7AC3_B)X<T2^\6WG@[PUI_BJYN+:&UD=
M(/'DCVPDB2\:$V\@V\C[Y^'EMK%EX \#6?B$2+K]IX/\,VVN+*%64:Q!HME%
MJ0D554"07JS9 51G. .E&WR#;Y'8T % !0 4 ?CY^U+_ ,EW\=?]RQ_ZAWAZ
M@#LIO&G@Z7P5\(+#6/B6FKZSX(\<P^(/$#V-IXXEUEM(FU+3U@BT?4M7\-VT
M3WVFZ; JXDN8DB2R"VAN"D44AM\@V^1H?%3QQ\-?B4OAS0[OQCHWA^%?&WB_
M5+K6?!OA3Q?_ ,(YI_A[4+9[FPU'Q#X=U2UL+G5O&][J2QI-=6$4B 7-T\DN
M"JN;>5@V\K&#H7Q1T6P\ ZHOB+4O"6L>(_\ A5&I_##PU!HVD>-HO%MMIFKS
MSF&S\0WM['9>&!8Z6D[,);2&\NI=D>)V;SFN#8-B#X3?%72O W@KP[I(\27.
MB:G_ ,+T\.Z[XBAM;74F>3X>)I=K;ZZTUQ:6<B36CW%K"DEE%(UQ*(AB%TZF
MP;'H]K\9?AM<7?@^[US6/M][X?\ '?Q-DTO4)](UB=O"/A[6X=2C\':C90/I
MNUM-LI1I1@TZV!DLD@A>*W22RBC!L&QD6_Q?\,Z98&.Y\<S:]XUL?@EX[\,M
M\0;:P\1I=ZKXHU?Q)I6J>$])M=2U'2K?5C<:5;6=PT6J7L-LD<D@D29)22#8
M-BQK'QE\/:AHOCG3]'^(-WH6M>*/A]\+@NMF+Q=91S>-/#\Z1>,EN9])TF:Z
M35;W1K>UL7OA 8;J."*&2X\E 5-@V+?B_P"-?@O7?^$PL1XJ-]I$EE\&7\+V
M5]H6N:AI<.I^'?$=G=^+[A-%N8+2,R1Z:DPG$LUF;Z*-;:.=@(]AL&QX;\</
M%NB>,=7T+5].\07NNZO/I<LGB:*'4O%.H^$=+U62[DW6_@T>-+&SU;3M.N C
M7LE@\#6]HU[';6LTR0$@ \0H * "@ H * "@ H * "@ H * "@ H ^QOV1?
M_CV\\6KXSTF^N-!\(6!>SUFXDC+V_B4#YFT2VMI,)<%'*R/=?\NI *'S6"D
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M_!CH?_RTH /^&;/C=_T(.H?^#'0__EI0 ?\ #-GQN_Z$'4/_  8Z'_\ +2@
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MO3;>.UL;&UC$<%O!&,*B*.I)RS,Q+,S,S$LQ)-O*P;>5C1H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P""/PQ_\I* #_AISXY_]#Y<?^"/PQ_\I* #_AISXY_]#Y<?^"/PQ_\ *2@
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M)Z)X7TF?5/ MMXG;PQXL\0Z:-+N+NR\0:GHKWUF]S:?97ADTJUF0V#8ZB\^
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M_P#WSH'_ ,C4 '_#7_PU_P"B4S_]\Z!_\C4 '_#7_P -?^B4S_\ ?.@?_(U
M'LOPC^,OPN^+-Y>:19^&[#P_KULIGM](U2RTIY-2LT0-+<:?/#%MGDA(;S8,
M!U3$@#(',0!](06\%I$EO:P0VT$>1'!!$D,2!F+,$CC4*N69B< <DGO0!-0
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ME^+]4\0>']!\)7FJ>%(/#FJ12V6MC6K/3WT:YB>WU-;29"@ .9\7?M3^!$\
M^(?&'P]UNVU8^%/$OP8AUN3Q!X7\8Z1I[>"/BE\3-"\(P^-=!_M73])?Q7X6
MU'0)?$UWHGB31)=1TB_ET=I;:>]A@EBD .ME_:;^#<&AVNNSZ[XE@CN_'#?#
M6+09_AE\4H?'2>//^$4OO'$'A6Z^'$G@Q?%=CJUUX2T^?4[2*YT:+[9!-:&U
M,S7]JMP ;$/Q^^%<_C"U\#+KVJQZW=ZS'X9M[RY\%>.;/PB?%DFF'5E\&/\
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M5(9]5CLQ)IU&P;'1?LR_!S5/A7;_ !&N]=M[BUN-9\;:SH7@BQO&T:2\\/\
MP4\(^(?$;?"SPJ9M"N[JV?3K*+Q%XCOK!&F%Q#9:_:V]Y%#>07$:FP;'U'0
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MZBL[-[E[AD:^\1:OJFHSJH,,$44M\\-O!:0PVT4**0Q^@?H<+0 4 % !0 4
M% !0 4 % &MH>AZMXEU:PT+0K"XU/5M3N$MK*RMDW2S2MDGDD+'$B!G>5RJ1
MHC.[*BD@ _6SX$? C2?A)I O+P6^I^-M3MU75]65=T5E$VUSI&D%U#1V2.%\
MR;"O<.@=PJ)%%$;?(-OD?05 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?2<1IXK^'!M]/U&UM;?[9ING,UI+JP!XS>VVJ^(/#WCKX.Z?\._B/-\1K_\
M:PUCQWX6UW4?AIX\T#P;X4TNT^,MKXR@^)EM\5M8\.VOAGR+/PQ9WT\$6CZS
M=ZA?M=IIUM:S?;954V\@V\CI_#X\?S?%G3#*W[0,?Q2B^.?B\^.#>CXE1?L^
MGX#12>+(O"JZ,FJJ/A;):MX,'P]$1\-J?&)U]I9-1/'B!P <CI&N?%;Q+X-\
M/^ =2\/?'"YUWPM\ ?VCO"_Q-NO$GA/X@6NAZ[X^$'AW2_",$&NZY91VGQ&O
M[Y+?6Y](U+29=7@D@N91!=+)<&)P#)TC0/&E[X6\2Z/X6TC]H*\\.+X"^"$7
MB[1_BW9?$FYO(_C#I7Q3TBZ\0CP)IGC6-DBT^U\/07\NJGP'$/!:16NE-HY$
M4$NP ZKP?HOQ;UG]HCQ-!X_^(GQ+T$7'Q ^)>FKX3TGX6_M-KX(U[X37&F>(
M1X L]/\ C#I'Q+;X.^$;P>$9_"^H'6M'\-:%XF@UW1Y--EU!M4N;PZF;!L=%
M\*OAWX@E_8G\;?"OP-#\1O#/Q-F^'GCCP0T/Q-N_B;!<Z;\2I?!?]C0CPSJ7
MQ,EF\CP2;MM.-G?^%9)?#R/)>7&GEKD7F3;RL&WE83QS=^'_ (H?"/0_!WP]
M^$'Q3\$:MX7N_@)HJ1W'P?\ %/@:_P#AGX=L/C;\'KG4?"7A;6?$7ANTAUNW
MTK3?#T]_+<^$?[>T.U@\!"^OKN&W&EOJ!MY!MY'#?$;0/C-X>M?$G@G0/$'Q
M?TSX4Z)^T%/8?\)-=:=^T3\8_&B?#V__ &?_ (?>+=):RU+X;_$C0?BOXK\)
M+\9M5\5Z6VH:%XFO#9W446GWX?2-.OX;8 B\5^#/C%J7@+QAJ5A\0OV@/$6L
M> _V3)O$7PRU'PYI_P 7_A*_BCXP:5K'Q1O_  NNJ?#_ %74I_$/B#Q=::;8
M>%=*G\/>*+S69]8AO8+C7;34KNXL;BU/T#]#M_%?ACQ]X!OO&?A?3]6_:"\0
M_"9?$?P4USQ;K-CXA^)?C7XCW6A:S;^-]-^(Z^ /$&G7%UXG@B.M:+\/;S5-
M&\"O;SZ;8ZEJTFC6=DUZB$ ][_9TC\01>%?%8OY/B"_A!OB#KDGPI7XK/XH?
MXAQ?#Q].T,QQ^)&\>C_A+<?\)E_PF+:>OBIFU9=)?2UGVQK"B 'T#0!^/G[4
MO_)=_'7_ '+'_J'>'J ,75_B1X2U3X?^%OA^/!WB.WL_"^K3ZK!J'_";Z9+<
MW3:G=PS:U!+%_P (&B1B6W%S':LI/V9Y8Y)1=K$T4QL&Q9E^*?A5]&\%^#I/
M %YJ'@3PIJNM:U>Z)K'C.>?5]=OM5M[F&-3XATC0-,_LFSMI)UE$-K8_O&A'
MF,2[,38-C3M/CQ)9^!_^$1A\/WL+?\*\O_AZ;:#Q,\'@AXM0U"[NI_%DO@E=
M&)?QHT-W('U'^U@'GS.8@I\FC8-CF/"/Q3_X17PWX=\/?V%]O_X1_P"+F@?%
M/[7_ &I]E^U?V'8+8_V%]G_LZ7R/.V[_ +;YDFS.W[._6C;Y!M\CO=-_:-GT
MP:='%X21X+;Q=X[\1:C"^N8_M'3?'4>HQ7>BI(-'W6,UJM^&COE,FY[9"UN$
M9XV-@V,6+XW6>GZ+)X8T7PC-:>'(/AKXQ\ :9;WWB-=0U2WN_&NL6.L:KXAO
MM2BT&UBOB)M/A5+&*RLT +$3 ' -@V)-2^.-GK6D:[H.I^$KK^R]=\"> ?!U
MP+#Q+#:7T-SX O7O[#5HKFX\-W47DW-PV);)K8D)E4N0Q#@V#8MZS^T -7NO
M%EP?"+0#Q18?#6Q,:>);J-[(?#S6;75S(EW8Z;:W);4!;>2'MY;26T+^;'+(
MZ"C8-CSWXE?$-/B!/H$HTF>TGT/2%TNYUG6-1L];\5>(FCE(MKKQ%KMCH>D1
MZG+:V$=I:0O)8^?L@=[BXN)9BRGZ!^AYG0 4 % !0 4 % !0 4 % 'T]^SG\
M#M=^(.NV7BJZGO\ 0?"6@W\5Q_:]G++9ZAJ6H6<JRI8Z)<H5>%HY%7SKQ#^Y
M^ZA,Q_=GZ!^A^LPXX]/QZ>YH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /+_&OQN^"_P -=5M]"^(OQ>^%_@#6[O3XM6M=
M&\:^/_"GA75;G2I[F[LX-3M]/UW5K6>;3Y+NPOH$N$C,;26<Z!BT+A0#C_\
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M1Z #_A&/A;_T=K^Q_P#^'Y\._P#R/0 ?\(Q\+?\ H[7]C_\ \/SX=_\ D>@
M_P"$8^%O_1VO['__ (?GP[_\CT '_",?"W_H[7]C_P#\/SX=_P#D>@ _X1CX
M6_\ 1VO['_\ X?GP[_\ (] !_P (Q\+?^CM?V/\ _P /SX=_^1Z #_A&/A;_
M -':_L?_ /A^?#O_ ,CT =-X0\,_L_QZ_82^./VM?V7&\-P2>=?VWASXX^$9
M]4O!&0R64;7US9QVL4I^5YQ(SHN=B;F#(;?(-OD?H;I?[3G[(^AZ=9:1I'[1
M/[.^G:9IUO':V5E:?&#X<16]M;Q+M2.-%\1\  9).22222223;RL&WE8O_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
5H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
